Management of Hepatitis C with High Viral Load at 8 Months of Pregnancy
At 8 months gestation with hepatitis C and high viral load, defer direct-acting antiviral (DAA) treatment until after delivery and breastfeeding, focus on supportive care during pregnancy, plan vaginal delivery unless obstetric indications exist, and avoid invasive procedures that increase transmission risk.
Current Pregnancy Management (Third Trimester)
No Treatment During Pregnancy (Standard Approach)
The most recent guidelines recommend deferring HCV treatment until the postpartum period 1. Women of reproductive age with HCV infection should be counseled to undergo antiviral treatment after delivery and breastfeeding 1. While emerging data suggests DAAs may be safe in pregnancy 2, 3, current standard practice remains to wait until after pregnancy.
Alternative: Consider DAAs on Case-by-Case Basis
If treatment during pregnancy is deemed necessary, DAA therapy may be considered only after thorough multidisciplinary discussion involving hepatology and obstetric specialists about potential risks and benefits 4, 1. This represents a newer, evolving recommendation with 94% consensus 1. The IDSA/AASLD guidelines now state that DAA treatment may be considered during pregnancy on a case-by-case basis 4.
Important caveat: At 8 months gestation, initiating DAAs would provide minimal benefit for reducing mother-to-child transmission, as approximately one-third of transmissions occur antenatally 2. Treatment would be more appropriately timed earlier in pregnancy (second trimester) if pursued at all.
Delivery Planning
Mode of Delivery
- Proceed with vaginal delivery - cesarean section does not reduce mother-to-child transmission in women with isolated HCV infection 1, 5
- Cesarean section should only be performed for standard obstetric indications, not for HCV status alone
Intrapartum Precautions to Minimize Transmission Risk
Avoid the following procedures that may increase vertical transmission risk 5:
- Internal fetal monitoring (fetal scalp electrodes)
- Episiotomy
- Prolonged rupture of membranes (manage labor actively)
- Chorionic villus sampling (if prenatal testing was being considered)
Amniocentesis can be performed if necessary for prenatal diagnosis, though non-invasive prenatal testing is preferred 1.
Postpartum Management
Breastfeeding
Breastfeeding should not be discouraged in HCV-infected mothers - it is safe and does not increase transmission risk 1, 5. This recommendation has 100% consensus and Grade 1A evidence 5.
Postpartum Treatment Planning
- Initiate DAA therapy after delivery and completion of breastfeeding 1
- Ledipasvir/sofosbuvir and sofosbuvir/velpatasvir have the most pregnancy exposure data if treatment during late pregnancy or early postpartum is considered 2
- Establish linkage to hepatology care immediately postpartum to prevent loss to follow-up
Infant Management
Testing Protocol
- The risk of mother-to-child transmission is approximately 5-9% with high viral load 2, 5
- Establish close follow-up for the infant to ensure appropriate HCV testing occurs (major challenge is loss to care) 2
- Standard testing occurs at 18 months or later per current protocols
Additional Considerations
Coinfection Screening
Screen for other sexually transmitted infections including HIV, syphilis, gonorrhea, chlamydia, and hepatitis B 5. If HIV coinfection exists, delivery decisions may be individualized based on detectable HIV RNA and HCV RNA levels 1.
Alcohol Counseling
Counsel complete abstinence from alcohol 5.
Key Pitfalls to Avoid
- Do not perform cesarean section solely for HCV indication - this does not reduce transmission and increases maternal morbidity
- Do not discourage breastfeeding - this is safe and evidence-based
- Do not use invasive fetal monitoring unnecessarily - increases transmission risk
- Do not delay postpartum linkage to care - loss to follow-up is a major barrier to HCV elimination
The evidence strongly supports conservative management at this late gestational age, with focus on safe delivery practices and aggressive postpartum treatment linkage 4, 1, 5.